A cancer vaccine suitable for lung, breast, prostate, colon and ovarian cancer has shown promising results in a vaccine trial conducted in Singapore. It was tested for the first time on four patients with Stage 4 cancer and no major side effects have been observed yet.
The vaccine trial was launched by the National Cancer Centre of Singapore in September 2014 in collaboration with the Singapore Clinical Research Institute and MicroVAX, a biotech company based in the United States.
One of the main objectives of this trial was to determine the safety in administration of the vaccine on human beings and it has seemed to meet this objective successfully. With optimistic results in the early stages of the first phase of the trial, a larger sample data would be required before moving into the second phase.
Click here for the full press release.